Document:

Exhibit 10.1

 

 

 

 

AMENDMENT NO. 3

 

 

 

 

To

 

 

 

MANUFACTURING SERVICES AGREEMENT

 

Dated as of 4 May 2018

 

 

Between

 

Proteon Therapeutics, Inc.

 

And

 

LONZA LTD

 

 

 

 

 

 

 

    Page 1 of 5

    

    

 

THIS AMENDMENT No. 3 ("Amendment 3")
is made effective as of the 4th day of May, 2018 to the Manufacturing Services Agreement, dated 30 June 2015 between Proteon Therapeutics,
Inc. (“Proteon” or “Customer”) and Lonza Ltd (“Lonza”), as amended from time to time (the “Agreement”),

 

 

BETWEEN:

 

Proteon Therapeutics Inc., having its
address at 200 West Street, Waltham, Massachusetts

 

and

 

Lonza Ltd., a Swiss Corporation having
a place of business at Münchensteinerstrasse 38, CH-4002 Basel, Switzerland

 

 

WHEREAS

 

		A.	Proteon and Lonza entered into the Agreement, under which Lonza is required to perform Services
relating to the Cell Line and Product described therein, and

 

		B.	Parties wish to make several changes to the Agreement.

 

NOW THEREFORE
THE PARTIES AGREE AS FOLLOWS:

 

		1.	The following terms shall be deleted in their entirety from Clause 1 and replaced with the following:

 

“Applicable Laws” means
all relevant federal, state and local laws, statutes, rules, and regulations of any Governmental Authority which are applicable
to a Party’s activities hereunder, including, without limitation, the applicable regulations and guidelines of any Governmental
Authority and all applicable cGMP together with amendments thereto.

 

“Batch” means a specific
quantity of Product that is intended to have uniform character and quality, within specified limits (including the Specifications),
and is derived from a single run of the Manufacturing Process at 1000L nominal volume (approx. 800L working volume). The minimum
yield requirements for each Batch (“Minimum Yield”) will be determined by the Parties in good faith after the release
of []* Batches (including the Process Validation Batches).

 

“Regulatory Authority”
means the FDA, EMA, and any similar regulatory authority in the []*. The terms “Regulatory Authority” and “Governmental
Authority” shall include any other regulatory authorities or governmental entities as may be agreed upon in writing by the
Parties, which agreement shall not be unreasonably withheld or delayed.

 

Capitalized terms used but not otherwise
defined herein shall have the meanings afforded to them in the Agreement.

 

		2.	Clause 6.2 of the Agreement is hereby amended by adding the following after the last sentence:

 

“Notwithstanding the forecasting
and ordering requirements set forth herein, the Parties agree that, in the event Customer wishes to manufacture one (1) cGMP Batch
coincident with a pre-approval inspection of Lonza by the FDA, Lonza will provide Customer with the first available production
slot for such Batch upon receipt of written notice from Customer. In addition, Lonza hereby agrees that Proteon’s Affiliates
shall have the right, from time to time, to order quantities of a Product hereunder (including one or more Batches of a Campaign),
provided that the acceptance of such order shall be subject to Lonza’s discretion, if the order is not in line with the Forecast.
Any such Affiliate shall be bound by the terms of this Agreement with respect to any purchase order placed directly with Lonza
hereunder and shall be deemed to have all of the rights and obligations of Customer under the Agreement. Proteon shall remain jointly
responsible and liable for the performance of the payment obligations related to such order by Proteon's Affiliate in the event
that a breach or failure of such a payment obligation relating to such order is not remedied by Proteon's Affiliate within []*
after written notice to the Proteon's Affiliate (with a copy to Customer hereunder) from Lonza requiring such breach or failure
to be remedied by Proteon's Affiliate, Proteon shall immediately fulfill all outstanding payment obligations.”

 

    * CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
Page 2 of 5

    

    

 

		3.	Clause 7.3.1 of the Agreement is hereby deleted in its entirety and replaced with the following:

 

“Promptly following Release
of Batches, Customer shall inspect such Batches and shall have the right to test such Batches to determine compliance with the
Specifications and, if applicable, the Minimum Yield. Customer shall notify Lonza in writing of any rejection of a Batch based
on any claim that it fails to meet Specifications or Minimum Yield within thirty (30) days of Release, after which time all unrejected
Batches shall be deemed accepted; provided that (a) Lonza provides timely answers to information requests and resolution of issues
arising from Customer’s review of such Batch (and the thirty (30) day period shall be extended to account for Lonza’s
failure to provide timely answers to information requests and resolution of such issues); and (b) failure to notify shall not prejudice
Customer’s right to reject or revoke acceptance of the Batch if the non-conforming condition causing the rejection of such
Batch could not have been detected by Customer’s inspection undertaken pursuant to this Clause 7.3.1; provided that any such
notification shall be provided to Lonza within []* of delivery of the Product. In the event that Customer desires to accept a Batch
prior to the end of the thirty (30) day period, Customer will provide written notice of such acceptance to Lonza.”

 

		4.	The first sentence of Clause 7.3.4 of the Agreement is hereby deleted in its entirety and replaced
with the following:

 

“7.3.4       Lonza
shall replace any Batch (except for an Engineering Batch) that failed to meet the Specifications (in each case, a “Failed
Batch”). Such replacement shall be made as promptly as practicable, in light of available manufacturing capacity and in any
case as soon as reasonably possible after confirmation of a Failed Batch. Where possible, such replacement Batch shall be manufactured
with the next scheduled cGMP Batch or Campaign. Customer acknowledges and agrees that its sole remedy with respect to a Failed
Batch is as set forth in this Clause 7.3.4, and in furtherance thereof, Customer hereby waives all other remedies at law or in
equity regarding the foregoing claims. Lonza shall not be responsible for the cost of Raw Materials or Customer Materials consumed
in any Failed Batch except to the extent set forth in this Clause 7.3.4.”

 

		5.	Clause 8.5.1 of the Agreement shall be deleted entirely and shall be replaced by the following
clause:

 

"8.5.1Upon reasonable prior
written notice, not more than once per calendar year, starting in January []* and on each succeeding anniversary thereafter, Lonza
may adjust the Batch Price in accordance with the US Department of Labor’s Bureau of Labor Statistics Pharmaceutical Preparations
Index, ethical PCU 325414 (or any successor index) (“PPI”) percentage change, if any, for the most recent twelve-month
period for which figures are available, provided that such adjustment shall not exceed []* of the Batch Price. The new Price reflecting
such Batch Price adjustment shall be effective for any Batch for which the Commencement Date is on or after the date of Lonza’s
notice to Customer of the Price adjustment."

 

		6.	Clause 8.5.2 of the Agreement shall be deleted entirely and shall be replaced by the following
clause:

 

"8.5.2In addition to the
above, the Price may be changed once per calendar year, starting in January []* and on each succeeding anniversary thereafter,
upon reasonable prior written notice to the Customer (providing reasonable detail and any other documentation reasonably requested
by Customer in support thereof), to reflect []* that has a material change of more than []* on Lonza’s cost to perform the
Services under this Agreement (as calculated on a pro rata basis based on Customer’s use of the Facility), provided that
such cost changes are not otherwise covered by PPI. In addition, the Parties will work diligently and in good faith to achieve
all feasible cost savings with respect to Lonza’s processes and materials and pass on at least []* of such savings to Proteon
in the form of Batch Price reductions."

 

    * CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
Page 3 of 5

    

    

 

		7.	For purposes of clarity, in accordance with Clause 11.1.1 of the Agreement, Lonza hereby agrees
that the Manufacturing Process was used to manufacture and deliver the Process Validation Batches and that, as of the date hereof,
no Lonza Information or Lonza Background Intellectual Property has been incorporated into such Manufacturing Process.

 

		8.	Clause 12.5 of the Agreement shall be delete entirely and shall be replaced by the following clause:

 

12.5       LIMITATION
OF LIABILITY. (A) EXCEPT FOR BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER CLAUSE 13 AND EXCEPT AS OTHERWISE PROVIDED IN CLAUSE 12.1
WITH RESPECT TO THIRD PARTY CLAIMS, LONZA’S LIABILITY TO THE CUSTOMER UNDER THIS AGREEMENT SHALL IN NO EVENT EXCEED, IN THE
AGGREGATE, THE GREATER OF (i) THE TOTAL AMOUNTS PAID BY CUSTOMER AND ITS AFFILIATES TO LONZA UNDER THE PURCHASE ORDER FOR THE CAMPAIGN
OR SPECIFIC MANUFACTURING SERVICES GIVING RISE TO SUCH CLAIM AND (ii) THE TOTAL AMOUNTS PAID BY CUSTOMER AND ITS AFFILIATES TO
LONZA UNDER THE PROJECT PLAN GIVING RISE TO SUCH CLAIM FOR DAMAGES IN THE TWELVE (12) MONTH PERIOD PRECEDING THE FIRST CLAIM FOR
DAMAGES, EXCEPT TO THE EXTENT RESULTING FROM LONZA’S FRAUD, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT.

 

(B) EXCEPT FOR BREACH OF CONFIDENTIALITY
OBLIGATIONS UNDER CLAUSE 13 AND EXCEPT AS OTHERWISE PROVIDED IN CLAUSE 12.2 WITH RESPECT TO THIRD PARTY CLAIMS, CUSTOMER’S
LIABILITY TO LONZA UNDER THIS AGREEMENT SHALL IN NO EVENT EXCEED, IN THE AGGREGATE, THE GREATER OF (i) THE TOTAL AMOUNTS PAID BY
CUSTOMER AND ITS AFFILIATES TO LONZA UNDER THE PURCHASE ORDER FOR THE CAMPAIGN OR SPECIFIC MANUFACTURING SERVICES GIVING RISE TO
THE CLAIM AND (ii) THE TOTAL AMOUNTS PAID BY CUSTOMER AND ITS AFFILIATES TO LONZA UNDER THE PROJECT PLAN GIVING RISE TO SUCH CLAIM
FOR DAMAGES IN THE TWELVE (12) MONTH PERIOD PRECEDING THE FIRST CLAIM FOR DAMAGES, EXCEPT TO THE EXTENT RESULTING FROM CUSTOMER’S
FRAUD, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT.

 

		9.	Clause 14.1 of the Agreement shall be delete entirely and shall be replaced by the following clause:

 

“14.1Term. This Agreement shall commence
on the Effective Date and shall have a term ending on June 30, 2029, which is the 14th anniversary of the Effective
Date, unless terminated earlier as provided herein or extended by mutual written consent of the Parties (the “Term”).
Notwithstanding the foregoing, each Project Plan may have separate term and termination provisions so long as the term of any Project
Plan does not extend beyond the Term.”

 

		10.	Clause 14.2.1 of the Agreement shall be delete entirely and shall be replaced by the following
clause:

 

“14.2.1       by
either Party for any reason upon 36 months' prior written notice to the other Party, provided that (i) Customer shall not exercise
this termination right before 1 January 2020; and (ii) Lonza shall not exercise this termination right before 1 January 2023;”

 

		11.	Parties agree to make the following changes to Project Plan A-1, Exhibit C and Exhibit D.

 

		a.	Exhibit C (Estimated Project Plan Timeline)

 

Subject to Section 6.1 and 6.2 of the
Agreement, the following table will be added to Exhibit C of Project Plan A-1 (as amended by Amendment 2, effective as of January
21, 2016), as a non-binding estimate of Customer’s commercial requirements for Batches:

 

[]*

 

    * CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
Page 4 of 5

    

    

 

For the sake of clarity, the Parties
hereby agree that the Batch scheduled for Q4 2019 is cancelled and no Cancellation Fee related thereto shall be due or payable.

 

		b.	Exhibit D (Price and Payment Terms)

 

Parties hereby agree that the payment
schedule set forth in Exhibit D is hereby deleted and the Batch Price of []* per Batch will be replaced by a Batch Price of []*
per Batch for all orders placed from and after the date hereof.

 

		12.	A new Clause 6.3.1 will be added between Clause 6.3 and Clause 6.4 of the Agreement:

 

“6.3.1       Minimum
Quantity. During the Term of this Agreement and expressly conditioned on the FDA’s approval of the Product (including,
but not limited to, FDA’s approval of Lonza as a supplier of the Product), Customer undertakes to order (by issuing binding
purchase orders pursuant to clause 6.2 of this Agreement) from Lonza a minimum of []*, starting in calendar year 2022. For example,
the []* forecasted in 2022 would be followed by []* in []*. For the avoidance of doubt, and subject to the first sentence of this
Clause 6.3.1, Parties agree that the first binding purchase order for the 2022 []* shall be issued ultimately on or before []*.
Unless otherwise agreed to by the Parties in writing, if Customer fails to place a binding purchase order for such []* within the
applicable []* period (including any purchase orders placed by an Affiliate of Customer for purposes of this calculation), Customer
shall pay the Price for []* not so ordered within []* days following the end of such period and receipt of Lonza’s invoice.”

 

		13.	Remainder of Agreement. All other terms and conditions of the Agreement (as previously amended)
shall remain in full force and effect.

 

		14.	Entire Agreement. This Amendment 3 and the Agreement supersede all other prior agreements,
understandings, representations and warranties, oral or written between the parties hereto in respect of the subject matter hereof.

 

 

AS WITNESS the hands of the duly authorized representatives
of the parties hereto the day and year first before written.

 

 

	SIGNED BY:	 	/s/ Bart van Aarnhem
	For and on behalf of	 	
	Lonza Ltd	 	Sr. Legal Counsel 
	 	 	Title
	 	 	 
	SIGNED BY:	 	/s/ Michael Stanek
	For and on behalf of	 	 
	Lonza Ltd	 	General Counsel
	 	 	Head Legal Team Basel
	 	 	Title
	 	 	 
	SIGNED BY:	 	/s/ Timothy Noyes
	For and on behalf of	 	Timothy P. Noyes
	Proteon Therapeutics, Inc.	 	 
	 	 	President and CEO
	 	 	Title
	 	 	 

 

 

 

* CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.

 

Page 5 of 5Exhibit

        
Exhibit 10.1

FORM OF CONFIDENTIALITY, NON-COMPETITION AND NON-SOLICITATION AGREEMENT
A.    I,                 , the undersigned employee, have been hired into the position of                  of UGI Corporation, a Pennsylvania corporation.  In connection with my employment, I will support UGI Corporation and its subsidiaries and affiliates (collectively, “UGI”) throughout the United States and internationally where UGI operates.  I will be responsible for,                 .  I will work closely with executive officers and senior management of the various business units and participate in meetings with UGI’s Board of Directors and committees.  I will also work closely with numerous vendors and suppliers of services to UGI. 
B.    I understand that UGI has and will put me in a position of trust and confidence and by disclosing to me, as well as having me develop, Confidential Information about its business and customers.  I acknowledge that UGI is in a highly competitive industry and that it has legitimate interests in maintaining and preserving its Confidential Information and customer relationships.  I am and will be privy to certain key business information, strategic plans and other highly Confidential Information about UGI's current and future business and participate in discussions and decision-making on these issues.  
C.    Accordingly, in consideration for the commencement of my employment, which I acknowledge is adequate and sufficient consideration, I agree to the terms of this Confidentiality, Non-Competition and Non-Solicitation Agreement (“Agreement”), as follows: 
1.    Recitals.
The recitals contained in the lettered paragraphs above are hereby incorporated and made a part of this Agreement.  
2.    Definitions.
a.    The term "Confidential Information" includes all confidential and proprietary information that UGI has developed, acquired, created, compiled, discovered or owns, that has value to UGI’s business and which is not generally known or otherwise available to the public and which UGI wishes to maintain as confidential, including, without limitation, information, whether in tangible form or otherwise, concerning actual or anticipated business, products, sales and marketing plans; technical data and trade secrets; past, present and prospective customer identities, lists, preferences, credit information and usage patterns; pricing and marketing policies and practices; financial and forecast information; compliance and related initiatives; risk profiles and tolerance; passwords, log-in information and other details relating to system access, databases and computer programs; contractual and other dealings with customers, vendors and suppliers; acquisition and strategic plans; executive compensation and personnel matters; and other operating policies and practices. 
b.    The term "Territory" refers to the 50 States of the United States and any other United States territories and foreign countries in which UGI conducts business.

1

c.    The term “UGI Customer” refers to any business or person who:  (i) purchased goods or services from UGI during the one-year period prior to the termination of my employment; or (ii) solicited or was solicited by, or received a proposal from, UGI to supply it with goods or services, where I had involvement in the preparation or presentation of such solicitation or proposal, during the six-month period prior to the termination of my employment.
3.    Confidential Information and UGI Property.
a.    I will protect the Confidential Information of UGI and its predecessors, as well as Confidential Information of any other party to whom UGI owes an obligation of non-disclosure, from disclosure and will not divulge it during or after my employment to any other person or entity not associated with UGI, except as necessary to fulfill my obligations, duties and responsibilities associated with my work on behalf of UGI.  To the extent that I am required to disclose Confidential Information in accordance with judicial proceedings or administrative orders, I shall give UGI reasonable notice prior to such disclosure and shall comply with any applicable protective order 
b.    All reports, manuals, memoranda, electronic information and data and other materials made available to me by UGI during the performance of my duties are the property of UGI, and I will use all such property exclusively for UGI's benefit and will return it, including copies, to UGI upon request of UGI, and in any event, without the requirement of a request, upon the termination of my employment.  I shall take reasonable security precautions and measures to maintain and protect the confidentiality of Confidential Information, and shall follow all policies and procedures of UGI regarding the handling, use, access, distribution, maintenance, and disclosure of same.  Nothing in this Agreement is intended to prevent any disclosure made in confidence to a government official or attorney, either directly or indirectly, solely for the purpose of reporting or investigating a suspected violation of law or in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
4.    Intellectual Property Ownership
a.    As used in this Agreement, “Company Innovations” means all inventions, creations, ideas (whether written or suggested), compositions, products, reports, outlines, improvements, modifications, processes, formulas, models, prototypes, sketches, drawings, plans or other works or material(s) for which I, alone or with one or more others, may make, devise or discover during my employment with UGI, including all ideas, inventions, creations, or plans written, suggested, created, produced, constructed, and/or contemplated including, but not limited to, items that pertain or are actually or potentially useful to any of the commercial or industrial activities, or processes and/or equipment for supporting same, of UGI.  Company Innovations do not include, however, any invention that I developed entirely on my own time without using UGI’s equipment, supplies, facilities or trade secret information, except for those inventions that either:  (1) relate at the time of conception or reduction to practice of the invention to the design, manufacturing, marketing or sale of goods or services that UGI distributes or sells; or (2) result from any work performed by me for UGI

2

b.    All Company Innovations shall be the sole and exclusive property of UGI and shall constitute “works made for hire” as that term is defined in the copyright laws of the United States.
c.    I agree to execute and deliver to UGI such assignments or other instruments as UGI may require from time to time to evidence UGI’s ownership of Company Innovations.
d.    I agree to waive any and all rights to Company Innovations.
e.    I shall, irrespective of the termination of my employment with UGI, give all information and data in my possession as to the exact working, producing, and using any inventions and will also at the expense of UGI give all such explanations, demonstrations, and instructions to UGI as UGI may deem appropriate to enable the full and effectual working production or use of the same.  At UGI’s expense, I shall, irrespective of the termination of my employment with UGI, promptly execute all acts, matters, documents, and perform all other acts necessary to enable UGI or its designated representative to apply for and obtain any and all applicable intellectual property rights in any and all countries relating to any Company Innovations.
5.    Non-competition and Non-solicitation.
During my employment and for a period of two years after the termination of my employment with UGI for any reason, voluntary or involuntary:
a.    I will not, for the benefit of myself or any other person or entity other than UGI, directly or indirectly, for the purpose or effect of competing or interfering with any part of UGI’s business:  (i) solicit or service the business of any UGI Customer within the Territory; or (ii) solicit or conduct business with any person or entity who is a vendor or supplier of any product or service to UGI in the Territory or induce any such vendor or supplier to terminate or reduce its relationship with UGI.  
b.    I will not, directly or indirectly:  (i) own or operate; (ii) acquire an equity or partnership interest or a controlling interest of any other kind in; (iii) accept employment from; or (iv) serve in any role including, without limitation, as a principal, director, officer, partner, consultant, agent, representative or advisor of or to, any business that, now or in the future, distributes or sells goods or provides services that compete with goods sold or services provided by UGI (including, without limitation, propane and/or natural gas) in the Territory without first obtaining the written consent of the                 of UGI Corporation.  Notwithstanding anything to the contrary herein, in the event that my employment is involuntarily terminated by UGI based upon my failure to meet the performance or financial objectives established for my position and UGI, in its sole discretion, determines that such failure on my part was not deliberate, UGI may, in its sole discretion, on a case by case basis, determine that a reduction in the two-year post-employment term is appropriate.  Nothing in this paragraph 5(b) shall prohibit me from passively investing in a publicly held business that competes with UGI provided my investment is less than 1% of the outstanding stock or market value of the business and I do not otherwise violate paragraph 3, 4, or 5 of this Agreement.

3

c.    I will not, directly or indirectly, nor will I induce any other person or entity to, solicit, recruit, offer employment or engagement to, hire, employ or engage (or participate in any of the foregoing), in a competing business, any employee or consultant of UGI over whom I had direct or indirect supervisory responsibility or with whom I worked, or who was employed or engaged by UGI within the Territory during the two-year period prior to the termination of my employment.  Furthermore, I shall not induce or attempt to induce any employee or consultant to terminate his or her employment or engagement with UGI.
6.    Remedies and Reformation.
a.    I understand that if I violate this Agreement, UGI will suffer irreparable harm; therefore, in addition to any other remedies available to it, UGI will be entitled to seek and obtain injunctive or equitable relief, including orders prohibiting violations of this Agreement, without the necessity of posting a bond.  The limitations in this Agreement which apply for a period of two years after termination of employment shall be enforced by a court from the date of the last breach or violation of the applicable restriction(s) up to four years after termination of employment.  If any provision of this Agreement shall be determined to be invalid or unenforceable to any extent, the parties to this Agreement authorize the court to modify it to the extent necessary to make the provision enforceable.  If any provision of this Agreement shall be determined to be invalid or unenforceable to any extent, such invalidity shall not impair the operation of or affect the remaining provisions hereof.
b.    In any legal proceeding in which UGI obtains injunctive or equitable relief or damages against me arising out of my violation of this Agreement, UGI shall be entitled to recover from me its reasonable attorneys' fees and costs.
c.    The failure by UGI to insist on my compliance with this Agreement or to enforce it in any particular circumstance will not constitute a waiver by UGI of its rights to seek relief for any other or subsequent breach of this Agreement.  Any breach by UGI of this Agreement or any other agreement between UGI and me, whether or not material, shall not constitute a defense to UGI’s enforcement of this Agreement against me.
7.    Additional Provisions.
a.    This Agreement shall continue to be in full force and effect without re-execution in the event that:  (i) I am employed by UGI in another position or transferred to another territory; (ii) I take a leave of absence; or (iii) there are periods between active employment during which I do not perform services for UGI.
b.    This Agreement was, and shall be deemed to have been, made in the Commonwealth of Pennsylvania.  This Agreement and all disputes or claims arising under or relating to this Agreement shall be governed by the laws of the Commonwealth of Pennsylvania without regard to its choice of law provisions.
c.    The Court of Common Pleas of Montgomery County and the United States District Court for the Eastern District of Pennsylvania (hereafter, the “Designated Courts”) shall 

4

have exclusive jurisdiction over disputes arising out of or relating to this Agreement.  Accordingly, both UGI and I agree to submit to the exclusive jurisdiction and venue of the Designated Courts, and each of us agrees to waive any right to contest personal jurisdiction and venue before the Designated Courts or to seek to transfer or otherwise object to or challenge such Designated Courts.
d.    I will disclose the existence of this Agreement to all of my prospective and actual employers.  I authorize UGI to disclose the existence of this Agreement and to provide a copy of this Agreement to any prospective and actual employer.
e.    I have read and understood this Agreement, believe it to be reasonable, and am signing it voluntarily.  I acknowledge that my obligations under this Agreement will not impose an unreasonable economic hardship on me and are reasonable and necessary to protect UGI’s legitimate business interests.  I further recognize that this Agreement may be enforced against me by a court of law or equity.  I also understand that the execution of this Agreement is a requirement of my employment with UGI and that UGI will expect me to adhere strictly to the terms of this Agreement both during and following my employment.
f.    I acknowledge that I am not bound by any agreement or understanding with any third party that would inhibit me in any way from working in my role for UGI.  To the extent that I have any confidentiality obligations or other restrictions under any applicable agreements with third parties, I agree not to violate the terms of any such agreements or use any such confidential information of third parties in my employment with UGI.
g.    The provisions of this Agreement constitute the entire agreement between me and UGI regarding UGI's Confidential Information and my non-competition and non-solicitation obligations, which Agreement cannot be varied except by a writing signed by me and the              of UGI Corporation.  Notwithstanding the foregoing, the provisions of this Agreement are in addition to, and not a limitation or substitution of, nor do they supersede the provisions of UGI Corporation’s Code of Business Ethics and Conduct, Employee Handbook or Human Resources Policies.
h.    I hereby consent to UGI Corporation's assignment of this Agreement to any direct or indirect affiliate, subsidiary, division, related company or entity of UGI Corporation and to any entity that acquires through purchase, merger or otherwise, the assets or stock of, or any interest in, UGI Corporation or any direct or indirect affiliate, subsidiary, division, related company or entity of UGI Corporation.  Any assignee shall have the same rights as UGI Corporation under this Agreement.
i.    I acknowledge that this Agreement is intended to benefit UGI Corporation, and its affiliates, subsidiaries, divisions, related companies or entities, successors and assigns, now existing or hereafter created.  I further acknowledge that the intended beneficiaries of the Agreement are entitled to enforce the provisions of this Agreement to the same extent as UGI Corporation.
    

5

Dated this ____ day of _____________ 201__

___________________________________        ____________________________________
Witness                        

                            
UGI Corporation

___________________________________        By:_________________________________
Witness

Title: _____________________________

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]